Condition

Small Cell Lung Cancer ( SCLC ) clinical trials and research

• 38Clinical trials
• 3New in 30 days
• 44Countries

Newest Small Cell Lung Cancer ( SCLC ) clinical trials

All recruiting trials (38)

• 68Ga-YQ-CC05: a new probe for detecting tumors with CCK2R

  This study tests a radioactive probe called 68Ga-YQ-CC05 to see if it can safely help find tumors in adults with certain cancers using PET-CT imaging.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07914764

• Exploration of whole-brain radiotherapy with PD-1 inhibitors for brain injury in SCLC

  This study tests whether adding PD-1 inhibitors to chemotherapy and prophylactic brain irradiation helps some small cell lung cancer patients protect the brain.

  Recruiting Guizhou Medical University · Guiyang, Guizhou · NCT07905937

• Propranolol with Adebrelimab and Platinum Chemotherapy in Small Cell Lung Cancer

  This early-phase trial tests whether adding propranolol to adebrelimab plus platinum chemotherapy is safe and may help treat small cell lung cancer in adults.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan and 3 other locations · NCT07886047

• IDP-121 plus chemotherapy in platinum-resistant small cell lung cancer

  This trial tests higher and higher doses of IDP-121 with chemotherapy to see if it is safe and workable for adults with advanced small cell lung cancer that progressed after first-line platinum therapy.

  Recruiting at 6 sites Phase 1/2 IDP Discovery Pharma S.L. · Barcelona and 9 other locations · NCT07864207

• Multiomic analysis in relapsed small-cell lung cancer with DLL3 T cell engager

  This observational study tests how blood and tumor markers change over time in adults with relapsed small-cell lung cancer who are receiving a DLL3-targeted therapy, to see if those changes relate to clinical outcomes.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07795411

• Multiomic analysis in relapsed small-cell lung cancer with DLL3 T cell engager

  This observational study tests how blood and tumor markers change over time in adults with relapsed small-cell lung cancer who are receiving a DLL3-targeted therapy, to see if those changes relate to clinical outcomes.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07795411

• Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers

  Aims to see if DLL3-SAVVYZ-IL18 CAR T cells can be safely given to people with DLL3-positive cancers, including certain small cell lung cancers and other neuroendocrine tumors.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07783477

• Adaptive Dual-Target CAR-NK Therapy for Relapsed or Refractory SCLC

  This trial tests three dual-target CAR-NK cell products to see if they are safe and show early signs of activity in adults with relapsed or refractory small cell lung cancer.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07744256

• TLN-499 plus venetoclax in relapsed or refractory solid tumors

  Doctors are testing whether TLN-499 added to venetoclax can help patients with relapsed or refractory solid tumors, including SCLC and certain neuroendocrine cancers.

  Recruiting Phase 1 Treeline Biosciences, Inc. · Camperdown, New South Wales and 2 other locations · NCT07713732

• DLL3-targeted PET/CT for small cell lung cancer

  This study tests whether DLL3-targeted PET/CT can better detect lesions in people with suspected or confirmed small cell lung cancer compared with standard imaging.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07677787

• THE-0504 in patients with solid tumors

  A first-in-human, dose-escalation study to see if THE-0504 is safe and tolerable in adults with solid tumors such as SCLC, CRC, GC, TNBC, and pancreatic cancer.

  Recruiting Phase 1 Thena Biotech S.r.l. · Rome, Lazio · NCT07646106

• Prospective cohort of SCLC patients receiving radiotherapy-based comprehensive treatment

  This project will collect detailed clinical, imaging, pathology, and molecular data from adults with limited-stage SCLC who receive radiotherapy with or without chemotherapy and immunotherapy to try to identify which radiotherapy timing, dose, and combinations work best.

  Recruiting Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT07565532

• IBI115 in Advanced Small Cell Lung Cancer (SCLC) explores safety and early activity

  This study tests IBI115 alone and with other therapies in adults with advanced SCLC to see if it is safe and shows signs of activity.

  Recruiting Phase 1 Innovent Biologics (Suzhou) Co. Ltd. · Chongqing, Chongqing Municipality · NCT07559019

• Dose-finding of EXS74539 (REC-4539) in select solid tumors

  This study will try different doses of the experimental drug EXS74539 in adults with select solid tumors to find a safe and tolerable dose.

  Recruiting at 3 sites Phase 1 Exscientia AI Limited · Los Angeles, California and 2 other locations · NCT07517198

• Tislelizumab treatment for people with lung cancer in routine care

  We will see how tislelizumab is used and how patients with resectable, locally advanced, or extensive-stage lung cancer do when treated in everyday clinical care in Germany and Austria.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sankt Pölten, Lower Austria and 1 other locations · NCT07510724

• Using a new PFD3 PET tracer to find and stage small cell lung cancer

  This test will try a new PET tracer called PFD3 in adults with small cell lung cancer to see if it detects tumors and stages disease more accurately than standard FDG PET/CT.

  Recruiting Phase 1/2 Peking University First Hospital · Beijing, Beijing Municipality · NCT07508852

• First-in-human ML261 CAR T therapy for relapsed/refractory SCLC and select neuroendocrine cancers

  This early-phase study tests whether a patient’s own ML261 CAR T cells can be safely given to see if they help people with relapsed or refractory SCLC or certain neuroendocrine cancers.

  Recruiting at 7 sites Phase 1 Moonlight Bio, Inc · St Louis, Missouri and 6 other locations · NCT07488923

• Adaptive Phase 1/2 testing dual-target CAR‑NK cells for relapsed or refractory small cell lung cancer

  This trial tests off-the-shelf dual-target CAR‑NK cell therapy in adults with relapsed or refractory extensive-stage small cell lung cancer to see if it is safe and can shrink tumors.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07480213

• PF-08634404 with or without chemotherapy for adults with transformed small cell lung cancer

  This will try the experimental drug PF-08634404 by itself and together with chemotherapy in adults whose EGFR-mutated non-small cell lung cancer has turned into transformed small cell lung cancer.

  Recruiting at 55 sites Phase 2 Pfizer · Duarte, California and 60 other locations · NCT07476287

• Obrixtamig with atezolizumab, carboplatin, and etoposide for advanced small cell lung cancer

  This trial will test whether adding obrixtamig to atezolizumab plus carboplatin and etoposide helps people with extensive-stage small cell lung cancer live longer.

  Recruiting at 166 sites Phase 3 Boehringer Ingelheim · Mobile, Alabama and 241 other locations · NCT07472517

• Alisertib plus paclitaxel for small cell lung cancer

  This study tests different doses of alisertib together with paclitaxel to see if patients with small cell lung cancer can tolerate the treatment.

  Recruiting at 11 sites Phase 2 Puma Biotechnology, Inc. · Reno, Nevada and 10 other locations · NCT07465757

• Adebrelimab for advanced small cell lung cancer in routine care

  This project will try adebrelimab, a PD-L1 blocker, in adults with extensive-stage small cell lung cancer to see how safe it is and how well it controls the disease in routine clinical care.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07434518

• Bemotuzumab with chemotherapy and anlotinib, then targeted radiotherapy for extensive-stage small cell lung cancer

  This phase 2 study tests whether a combination of bemotuzumab, chemotherapy, and anlotinib, followed by continued bemotuzumab and anlotinib with thoracic radiotherapy, can help untreated extensive-stage small cell lung cancer.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07358676

• Sacituzumab govitecan with atezolizumab or durvalumab as maintenance for extensive-stage small cell lung cancer

  This study tests whether adding sacituzumab govitecan to ongoing atezolizumab or durvalumab can better control tumors in adults with extensive-stage small cell lung cancer after initial platinum-based chemotherapy.

  Recruiting Phase 2 Henry Ford Health System · Detroit, Michigan · NCT07339059

• DLL3-targeted alpha radiotherapy ([212Pb]Pb-MP0712) for advanced small cell lung cancer and DLL3-positive neuroendocrine tumors

  This will test a DLL3-targeted radioactive drug ([212Pb]Pb-MP0712) to see if it's safe and can shrink tumors in adults with advanced small cell lung cancer or other DLL3-positive neuroendocrine cancers.

  Recruiting at 8 sites Phase 1/2 Molecular Partners AG · Tampa, Florida and 7 other locations · NCT07278479

• TC-D101 CAR-T therapy for DLL3-positive small cell lung cancer

  This trial will try a single infusion of TC-D101 CAR-T cells in adults with DLL3-positive relapsed or refractory small cell lung cancer who have progressed after prior treatments.

  Recruiting Early Phase 1 TCRCure Biopharma Ltd. · Nanjing, Jiangsu · NCT07246304

• PF-08634404 plus chemotherapy for extensive-stage small cell lung cancer

  This study will try adding PF-08634404 to chemotherapy in adults with extensive-stage small cell lung cancer to see if it works better than current first-line treatment.

  Recruiting at 82 sites Phase 2/3 Pfizer · Fayetteville, Arkansas and 81 other locations · NCT07226999

• 177Lu-BetaBart treatment for relapsed, inoperable, or metastatic solid tumors

  This trial will test a radioactive antibody called 177Lu-BetaBart in adults whose solid tumors have progressed after prior treatment, including castration-resistant prostate, colorectal, lung, ovarian, or cervical cancer.

  Recruiting at 5 sites Phase 1/2 Radiopharm Theranostics, Ltd · Dothan, Alabama and 4 other locations · NCT07189871

• Lurbinectedin with Osimertinib for transformed small cell lung cancer

  This study tests a drug combo (lurbinectedin plus osimertinib) to see if it can help adults whose EGFR-mutated non-small cell lung cancer has transformed into small cell lung cancer.

  Recruiting Phase 1/2 Indiana University · Indianapolis, Indiana · NCT07153055

• Adjuvant chemotherapy plus durvalumab after complete resection of small cell lung cancer

  This phase II study tests whether adding durvalumab immunotherapy to standard adjuvant chemotherapy helps adults with completely resected early-stage small cell lung cancer stay cancer-free longer.

  Recruiting at 6 sites Phase 2 Alliance Foundation Trials, LLC. · Chicago, Illinois and 5 other locations · NCT07149363

• CP-383 for advanced or metastatic solid tumors

  This trial tests whether the oral drug CP-383 can slow or stop growth in adults with advanced or metastatic solid tumors who have exhausted standard treatments.

  Recruiting at 13 sites Phase 1/2 Tasca Therapeutics · Denver, Colorado and 12 other locations · NCT07030257

• Using Adebrelimab with chemotherapy for early-stage small cell lung cancer

  This study is testing if adding Adebrelimab to chemotherapy helps people with early-stage small cell lung cancer do better before surgery compared to just chemotherapy alone.

  Recruiting Phase 2 Tang-Du Hospital · Xi'an, Shannxi · NCT06485544

• Using 177Lu-anti-PD-L1 for treating metastatic solid tumors

  This study is testing a new treatment called 177Lu-RAD204 to see if it can safely help people with advanced solid tumors like lung cancer and melanoma.

  Recruiting at 4 sites Early Phase 1 Radiopharm Theranostics, Ltd · Gosford, New South Wales and 5 other locations · NCT06305962

• Testing Peluntamig for Neuroendocrine Carcinomas

  This study is testing a new drug called Peluntamig to see if it can safely help people with different types of neuroendocrine cancers, either on its own or with chemotherapy.

  Recruiting at 15 sites Phase 1/2 Phanes Therapeutics · Duarte, California and 14 other locations · NCT05652686

• Evaluating JAB-2485 for Advanced Solid Tumors

  This study is testing a new drug called JAB-2485 to see if it is safe and can help adults with advanced solid tumors, like certain types of breast cancer and lung cancer, who have already tried other treatments.

  Recruiting at 8 sites Phase 1/2 Jacobio Pharmaceuticals Co., Ltd. · Detroit, Michigan and 7 other locations · NCT05490472

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Treatment of solid tumors or lymphoma with VMD-928

  This study is testing a new oral medication called VMD-928 to see if it can help adults with advanced solid tumors or lymphoma that haven't improved with standard treatments.

  Recruiting at 13 sites Phase 1/2 VM Oncology, LLC · Santa Rosa, California and 12 other locations · NCT03556228

• Treatment of advanced cancers with Mevrometostat

  This study is testing a new drug called Mevrometostat to see if it can help people with advanced cancers like small cell lung cancer, prostate cancer, and follicular lymphoma feel better and improve their treatment outcomes.

  Recruiting at 22 sites Phase 1 Pfizer · Tucson, Arizona and 84 other locations · NCT03460977

Related topics

Quick answers

How many Small Cell Lung Cancer ( SCLC ) clinical trials are recruiting right now?

38, as of November 12, 2026. 3 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 44 countries. The most sites are in United States (19 trials), China (18 trials), Spain (7 trials), Australia (6 trials), France (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 12, Phase 1: 8, Phase 2: 6, Early Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →